Insmed (NASDAQ: INSM) reported Q3 EPS of ($1.27), $0.07 worse than the analyst estimate of ($1.20). Revenue for the quarter came in at $93.42 million versus the consensus estimate of $93.35 million.

GUIDANCE:

Insmed sees FY2024 revenue of $340-360 million, versus the consensus of $357.1 million.

For earnings history and earnings-related data on Insmed (INSM) click here.